Health & Biotech
The Health Kick Podcast with Tim Boreham: BioScience Managers
Health: “New Gastro Weapon” sends Immuron shares flying 124pc
Clinuvel shares seesaw as D-Day approaches
Health: Actinogen recovers some hope from Xanamem wreckage
These Aussie small caps are trying to tackle the opioid crisis
Health: Cross-continental expansion moves shares for germ killer Zoono
Dr Boreham’s Crucible: Suda shows far more promise than its ‘penny-dreadful’ status suggests
Rhythm Biosciences’ cheap, effective cancer test could be a godsend to overburdened medical systems
Health: Bionomics heading towards redo of failed PTSD trial, shares fly 81pc
The Health Kick Podcast with Tim Boreham: Oventus Medical
Weed week: Canberra leads the way on cannabis, makes pot possession legal
3D bone implant printing biotech Osteopore joins the ASX
Shares in 3D body implant printer Osteopore up 300pc on ASX debut
Health: Immutep bounces off decade-long lows thanks to cash from GSK
Dr Boreham’s Crucible: PharmAust wants a piece of the +$US10.2b pet drug market
Health: Respiri will begin a 4,500-bed trial of its ‘wheezo’ asthma device in India next month
When is the right time for a biotech to try and woo big pharma?
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
